Currently out of the existing stock ratings of Salveen Richter, 97 are a HOLD (34.77%), 164 are a BUY (58.78%), 18 are a SELL (6.45%).

Salveen Richter

Work Performance Price Targets & Ratings Chart

Analyst Salveen Richter, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 65.63% that have a potential upside of 34.24% achieved within 268 days.

Salveen Richter’s has documented 559 price targets and ratings displayed on 49 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on QURE, Uniqure NV at 12-Dec-2024.

Wall Street Analyst Salveen Richter

Analyst best performing recommendations are on KRTX (KARUNA THERAPEUTICS).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 11/18/2019. The price target of $109 was fulfilled within 1 day with a profit of $13 (13.54%) receiving and performance score of 135.42.

Average potential price target upside

of $471.43 (27.41%) on ACOR (ACORDA THERAPEUTICS).
of $216.94 (31.9%) on REGN (REGENERON PHARMACEUTICALS).
of $75.33 (38.32%) on VRTX (VERTEX PHARMACEUTICALS).

ACAD ACADIA Pharmaceuticals ACOR Acorda Therapeutics ADPT Adaptive Biotechnologies Corp AGIO Agios Pharm ALLO Allogene Therapeutics ALNY Alnylam Pharmaceuticals BLUE Bluebird bio BMRN Biomarin Pharmaceutical BPMC Blueprint Medicines Corp CRSP Crispr Therapeutics AG DNLI Denali Therapeutics DTIL Precision BioSciences GWPH GW Pharmaceuticals plc ICPT Intercept Pharmaceuticals INCY yte KRTX Karuna Therapeutics MDGL Madrigal Pharmaceuticals MRNA Moderna MRTX Mirati Ther NTLA Intellia Therapeutics RETA Reata Pharmaceuticals SAGE Sage Therapeutic SANA Sana Biotechnology SGEN Seagen SRPT Sarepta Therapeutics TSHA Taysha Gene Therapies VRTX Vertex Pharmaceuticals ARWR Arrowhead Pharmaceuticals ATRA Atara Biotherapeutics BIIB Biogen CNTA Centessa Pharmaceuticals PLC ADR PASG Passage Bio REGN Regeneron Pharmaceuticals RXRX Recursion Pharmaceuticals GILD Gilead Sciences RDUS Schnitzer Steel Industries AMGN Amgen QURE Uniqure NV TSVT 2Seventy Bio ADSK Autodesk FOLD Amicus Therapeutics IONS Ionis Pharmaceuticals LYEL Lyell Immunopharma ONCE Spark Therapeutics RARE Ultragenyx RCUS Arcus Biosciences SLDB Solid Biosciences LLC APLS Apellis Pharmaceuticals FDMT 4D Molecular Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Andrew Fein (HC WAINWRIGHT)